Get Skinny
The leadStraight reporting on GLP-1s, weight-loss medicine, and the programs behind them.
A plain white injection pen with a grey cap resting on a folded linen napkin beside a glass of water and two small bowls of berries on a sunlit kitchen counterThe Medications
Photo illustration

Saxenda microdosing: why a daily liraglutide pen changes the math, and the 16-week test it quietly breaks

Saxenda microdosing borrows an idea from weekly semaglutide and applies it to a drug that leaves the body in about a day. The one dose-ranging trial we have shows every step down the ladder costs real weight, and staying low makes it impossible to run the label's own check on whether the drug is working at all.

Reviewed Nov 20264 sources cited

By Maeve Castellucci · November 19, 2026 · 7 min read

The full file

Everything we have reported

68 stories

Pulling the next stories

Common questions

What readers
ask us.

  • GLP-1 receptor agonists (semaglutide, tirzepatide) mimic gut hormones that signal satiety, slow gastric emptying, and modulate insulin response. Patients typically experience reduced appetite and food noise. Published trials show 15-20%+ body weight loss with sustained use.

The Briefing

The latest, in your inbox.

A short, occasional dispatch on medically supervised weight solutions, new research, treatment advances, and the stories worth your time. No spam, unsubscribe anytime.

We send rarely and never sell your information.